当前位置: X-MOL 学术Transpl. Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Circulating microvesicle protein is associated with renal transplant outcome.
Transplant Immunology ( IF 1.5 ) Pub Date : 2019-06-19 , DOI: 10.1016/j.trim.2019.06.002
Khalid Al-Nedawi 1 , Sandor Haas-Neill 1 , Azim Gangji 1 , Christine M Ribic 1 , Anil Kapoor 2 , Peter Margetts 1
Affiliation  

Renal transplantation is an effective therapy with improved long-term outcomes compared with other therapies for end stage renal disease. Present methods for evaluating kidney allograft function, such as serum creatinine or allograft biopsy, are not sensitive and identify pathological changes only after any potential intervention would be effective. Thus, there is a necessity for biomarkers that would provide early prognostic information about kidney transplant outcomes. Circulating microvesicles represent an attractive source of biomarkers for different diseases including renal failure. We have studied the proteins of the circulating microvesicles from two populations of kidney transplant recipients (n = 20) with poor transplant outcomes (n = 10) or good transplant outcome (n = 10), according to their estimated glomerular filtration rate (eGFR). Microvesicles from age-matched healthy subjects (n = 10) were used as a control. Also, we performed a pilot study to assess the microvesicle protein in kidney transplant recipients before and six months after kidney transplant (n = 6), compared to healthy subjects. Proteomic analysis of microvesicles could discriminate between transplant recipients and healthy subjects, and between transplant patients based on eGFR. Our results shed light on the potential of blood microvesicles to provide a novel tool for the prediction of the outcome of kidney transplants.



中文翻译:

循环微泡蛋白与肾移植结果有关。

与其他针对终末期肾脏疾病的疗法相比,肾移植是一种具有改善的长期预后的有效疗法。目前用于评估肾脏同种异体移植功能的方法(例如血清肌酐或异体移植活检)并不敏感,只有在任何可能的干预措施有效后才能确定病理变化。因此,有必要提供生物标志物,以提供有关肾脏移植结局的早期预后信息。循环微泡代表了包括肾脏衰竭在内的各种疾病的生物标志物的诱人来源。我们研究了来自两个肾脏移植受者(n  = 20)的移植微循环蛋白的蛋白质,这些移植物的移植效果差(n  = 10)或移植效果好(n  = 10),根据其估计的肾小球滤过率(eGFR)。使用年龄匹配的健康受试者(n  = 10)的微泡作为对照。此外,我们进行了一项初步研究,以评估 与健康受试者相比,肾移植之前和之后六个月(n = 6)的肾移植受者中的微泡蛋白。微囊泡的蛋白质组学分析可以区分移植受者和健康受试者,以及基于eGFR的移植患者。我们的研究结果揭示了血液微泡为预测肾移植结果提供新工具的潜力。

更新日期:2019-06-19
down
wechat
bug